ATXN3 and Cognitive impairment: Thieme and colleagues concluded that whilst the CCAS-S may be of use in quantifying cognitive impairment in some of the SCAs (such as SCA3) utility for detection of cognitive impairment is less so in SCAs with differing underlying cerebellar/cerebral pathology such as SCA6 and FRDA [11].